Total Payments
$141,944
2024 Payments
$9,514
Companies
51
Transactions
1,041
Medicare Patients
1,636
Medicare Billing
$100,807
Payment Breakdown by Category
Other$92,927 (65.5%)
Food & Beverage$20,994 (14.8%)
Consulting$17,781 (12.5%)
Travel$9,776 (6.9%)
Education$466.14 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $68,808 | 41 | 48.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $24,120 | 8 | 17.0% |
| Food and Beverage | $20,994 | 925 | 14.8% |
| Consulting Fee | $17,781 | 9 | 12.5% |
| Travel and Lodging | $9,776 | 25 | 6.9% |
| Education | $466.14 | 33 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $39,054 | 87 | $0 (2024) |
| Incyte Corporation | $38,664 | 42 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $20,962 | 104 | $0 (2024) |
| Allergan, Inc. | $19,082 | 133 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $9,243 | 16 | $0 (2017) |
| Galderma Laboratories, L.P. | $2,546 | 71 | $0 (2024) |
| ABBVIE INC. | $2,526 | 120 | $0 (2024) |
| MERZ NORTH AMERICA, INC. | $1,240 | 14 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $1,090 | 67 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $682.77 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,514 | 89 | Incyte Corporation ($7,750) |
| 2023 | $7,662 | 103 | Incyte Corporation ($5,154) |
| 2022 | $24,144 | 108 | Incyte Corporation ($22,636) |
| 2021 | $9,154 | 129 | Incyte Corporation ($3,124) |
| 2020 | $7,114 | 108 | PFIZER INC. ($3,385) |
| 2019 | $24,243 | 172 | PFIZER INC. ($15,992) |
| 2018 | $26,887 | 175 | Ortho Dermatologics, a division of Bausch Health US, LLC ($12,247) |
| 2017 | $33,228 | 157 | PFIZER INC. ($13,523) |
All Payment Transactions
1,041 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,187.50 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $17.83 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,137.50 | General |
| Category: Dermatology | ||||||
| 12/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $14.85 | General |
| 12/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $2.37 | General |
| 11/23/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $19.63 | General |
| 11/21/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $144.72 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $29.88 | General |
| Category: Dermatology | ||||||
| 11/18/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: DERMATOLOGY | ||||||
| 11/18/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $5.40 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: Dermatology | ||||||
| 11/01/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.71 | General |
| Category: FACIAL AESTHETICS | ||||||
| 10/30/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $22.57 | General |
| 10/30/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $15.20 | General |
| Category: DERMATOLOGY | ||||||
| 10/28/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Dermatology | ||||||
| 10/22/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,137.50 | General |
| Category: Dermatology | ||||||
| 10/22/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Dermatology | ||||||
| 10/07/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | Incyte Corporation | OPZELURA (Drug) | Travel and Lodging | Cash or cash equivalent | $640.00 | General |
| Category: Dermatology | ||||||
| 10/03/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $29.88 | General |
| Category: Dermatology | ||||||
| 10/02/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $1.55 | General |
| 10/01/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 285 | 546 | $120,858 | $18,830 |
| 2022 | 7 | 313 | 515 | $96,192 | $20,371 |
| 2021 | 8 | 423 | 714 | $109,927 | $27,113 |
| 2020 | 8 | 615 | 918 | $73,953 | $34,492 |
Total Patients
1,636
Total Services
2,693
Medicare Billing
$100,807
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 86 | $22,618 | $4,692 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 44 | $16,368 | $3,947 | 24.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 53 | 63 | $23,814 | $3,821 | 16.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 22 | 28 | $11,732 | $2,158 | 18.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 53 | 69 | $20,950 | $2,091 | 10.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 21 | 32 | $6,560 | $1,099 | 16.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 36 | 224 | $18,816 | $1,022 | 5.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 93 | 116 | $21,693 | $6,864 | 31.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 47 | 57 | $16,181 | $3,787 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 27 | 35 | $9,562 | $2,924 | 30.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 34 | 36 | $12,080 | $2,839 | 23.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 55 | 65 | $19,516 | $2,129 | 10.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 18 | 24 | $3,713 | $931.41 | 25.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 39 | 182 | $13,446 | $896.70 | 6.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 116 | 155 | $24,932 | $9,282 | 37.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 62 | 74 | $17,859 | $4,363 | 24.4% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 46 | 53 | $15,288 | $3,977 | 26.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 41 | $9,262 | $3,547 | 38.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 73 | 100 | $23,994 | $3,288 | 13.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 58 | 248 | $13,096 | $1,069 | 8.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 22 | 27 | $3,203 | $941.88 | 29.4% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 12 | 16 | $2,294 | $644.15 | 28.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 132 | 157 | $19,468 | $10,968 | 56.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 100 | 114 | $13,509 | $6,728 | 49.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 92 | 117 | $11,583 | $4,922 | 42.5% |
About Dr. Jenny Sobera, MD
Dr. Jenny Sobera, MD is a Dermatology healthcare provider based in Mountain Brk, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063460343.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jenny Sobera, MD has received a total of $141,944 in payments from pharmaceutical and medical device companies, with $9,514 received in 2024. These payments were reported across 1,041 transactions from 51 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($68,808).
As a Medicare-enrolled provider, Sobera has provided services to 1,636 Medicare beneficiaries, totaling 2,693 services with total Medicare billing of $100,807. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Mountain Brk, AL
- Active Since 05/05/2006
- Last Updated 04/04/2025
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1063460343
Products in Payments
- EUCRISA (Drug) $39,036
- OPZELURA (Drug) $38,664
- ONEXTON (Drug) $9,514
- ELIDEL (Drug) $9,305
- JUBLIA (Drug) $4,636
- ALTRENO (Drug) $4,568
- ACZONE (Drug) $2,063
- DUOBRII (Drug) $1,261
- MIRVASO (Drug) $900.00
- COSENTYX (Biological) $767.51
- BOTOX (Biological) $753.12
- Humira (Biological) $576.27
- DORYX (Drug) $542.85
- EPIDUO FORTE (Drug) $506.78
- SOOLANTRA (Drug) $449.20
- TALTZ (Drug) $439.55
- SILIQ (Drug) $416.58
- VTAMA (Drug) $346.55
- RINVOQ (Biological) $344.61
- SKYRIZI (Biological) $328.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.